Protection against the omicron variant from previous SARS-CoV-2 infection
![Thumbnail](/xmlui/bitstream/handle/10576/32089/nejmc2200133.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2022-03-31Author
Altarawneh, Heba N.Chemaitelly, Hiam
Hasan, Mohammad R.
Ayoub, Houssein H.
Qassim, Suelen
AlMukdad, Sawsan
Coyle, Peter
Yassine, Hadi M.
Al-Khatib, Hebah A.
Benslimane, Fatiha M.
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H.
Latif, Ali N.
Shaik, Riyazuddin M.
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed G.
Butt, Adeel A.
Al-Romaihi, Hamad E.
Al-Thani, Mohamed H.
Al-Khal, Abdullatif
Bertollini, Roberto
Tang, Patrick
Abu-Raddad, Laith J.
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the B.1.1.529 (omicron) variant harbors multiple mutations that can mediate immune evasion. We estimated the effectiveness of previous infection in preventing symptomatic new cases caused by omicron and other SARS-CoV-2 variants in Qatar. In this study, we extracted data regarding coronavirus disease 2019 (Covid-19) laboratory testing, vaccination, clinical infection data, and related demographic details from the national SARS-CoV-2 databases, which include all results of polymerase-chain-reaction (PCR) testing, vaccinations, and hospitalizations and deaths for Covid-19 in Qatar since the start of the pandemic.
Collections
- Biomedical Research Center Research [727 items ]
- COVID-19 Research [818 items ]